Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Obstructive Sleep Apnea
NCT05303935Phase 2Completed
- Sponsor
- Flinders University
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quetiapine (extended-release tablet, brand name: Bipresso) in obstructive sleep apnea (OSA), Insomnia, sponsored by Flinders University. Started May 2022; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
obstructive sleep apnea (OSA)Insomnia
Beyond the preview
Go deeper on NCT05303935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303935.